Centinel Spine pairs NYSE filing with expanded prodisc approval
The disc replacement specialist filed for a NYSE listing as CNTL. A later FDA approval expanded its cervical portfolio, while IPO terms remain open.
Centinel Spine Holdco filed for a proposed NYSE listing on October 7, 2026. Its investor announcement identifies CNTL as the intended ticker. The SEC filing index confirms the public registration date.
The prospectus reports first half 2026 net revenue of $85.2 million, up 42% from $60.1 million a year earlier. The proposed transaction uses a holding company structure: public shareholders would own stock in the holding company, which would control the operating business. That makes the ownership arrangements relevant alongside the operating results.
The frequently cited $100 million figure requires care. It appears in the filing fee exhibit as the maximum aggregate amount used to calculate registration fees. With no share count or price range specified in the preliminary offer, it should not be presented as an agreed fundraising target or completed raise.
The operating story also moved forward after the filing. On October 14, Centinel announced FDA approval for use of prodisc C Nova at two cervical levels. The company said this brings C Nova alongside C Vivo and C SK as three cervical devices approved for procedures involving either one or two levels.
Centinel focuses on artificial disc replacement intended to preserve movement in the neck and lower spine. The approval broadens the range of procedures supported by its existing product family. It does not set the terms of the securities offering. For the proposed listing, the next milestones remain an updated prospectus with an actual price range and share count, followed by final pricing if the transaction proceeds.